Phathom Pharmaceuticals (PHAT) closed at $5.92 on November 2, 2026, up 3.0% from the previous close, on volume of 2,668,825 shares (30-day average 1,485,603).
Data as of November 2, 2026.
2-Nov-2026
Leerink Partners Sticks to Their Hold Rating for Phathom Pharmaceuticals (PHAT)
TipRanks (Mon, 2-Nov 11:42 AM ET)
Phathom Pharmaceuticals (PHAT) Receives a Buy from H.C. Wainwright
TipRanks (Fri, 30-Oct 6:37 AM ET)
TipRanks (Fri, 30-Oct 5:50 AM ET)
Phathom’s VOQUEZNA hits 2 million prescriptions as Q3 revenue reaches $84.7 million
Market Chameleon (Thu, 29-Oct 4:34 AM ET)
Phathom Pharmaceuticals Non-GAAP EPS of $0.04 beats by $0.01, revenue of $84.7M misses by $0.12M
Seeking Alpha News (Thu, 29-Oct 7:50 AM ET)
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 29-Oct 7:00 AM ET)
Phathom Pharmaceuticals Provides Update on FDA Litigation
Globe Newswire (Mon, 26-Oct 4:00 AM ET)
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
Globe Newswire (Fri, 23-Oct 4:00 AM ET)
Globe Newswire (Mon, 19-Oct 8:00 AM ET)
Globe Newswire (Mon, 12-Oct 8:00 AM ET)
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Phathom Pharmaceuticals trades on the NASDAQ stock market under the symbol PHAT.
As of November 2, 2026, PHAT stock price climbed to $5.91 with 2,668,825 million shares trading.
PHAT has a beta of 1.26, meaning it tends to be more sensitive to market movements. PHAT has a correlation of 0.06 to the broad based SPY ETF.
PHAT has a market cap of $480.84 million. This is considered a Small Cap stock.
Last quarter Phathom Pharmaceuticals reported $85 million in Revenue and $.04 earnings per share. This fell short of revenue expectation by $-373,920 and exceeded earnings estimates by $.02.
In the last 3 years, PHAT traded as high as $19.71 and as low as $2.21.
The top ETF exchange traded funds that PHAT belongs to (by Net Assets): VTI, IWM, VXF, XPH, IBB.
PHAT has underperformed the market in the last year with a price return of -55.6% while the SPY ETF gained +11.7%. PHAT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.5% and -14.5%, respectively, while the SPY returned +1.7% and -1.5%, respectively.
PHAT support price is $5.49 and resistance is $5.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHAT shares will trade within this expected range on the day.
